Novartis (NVS) has released an update.
Novartis has reported a robust third quarter in 2024, showcasing a 10% increase in net sales and a 20% rise in core operating income, driven by strong performances from key drugs like Entresto and Cosentyx. The company has raised its full-year guidance, reflecting confidence in its growth prospects and innovation milestones, including significant FDA approvals. With a free cash flow surge to USD 6 billion, Novartis demonstrates operational excellence and strategic focus on high-growth therapeutic areas.
For further insights into NVS stock, check out TipRanks’ Stock Analysis page.
